Open access
Aug 2026
Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017–2024
Eight years of VAERS data are consistent with the recognized reactogenicity of the recombinant vaccine and the live-vaccine profile of Zostavax; most reported events were transient and non-serious.
Mohammed Alkharaiji, Salahaden R. Sultan, Yousif A. Kariri et al.
· Frontiers in Medicine · 0 citations